Macquarie Analyst Comments on ResMed’s Maintained Revenue Guidance
ResMed maintained its annual revenue guidance at US$5.75 billion to US$5.85 billion. A Macquarie analyst said the decision suggests underlying operational improvement.
ResMed maintained its annual revenue guidance at US$5.75 billion to US$5.85 billion. A Macquarie analyst said the decision suggests underlying operational improvement.